✦ LIBER ✦

Real World Outcomes in Type 2 Diabetes: Lower Cost of Treating Patients to A1c<7% with Liraglutide Versus Exenatide

✍ Scribed by Dekoven, M.; Lee, W.C.; Bouchard, J.R.; Massoudi, M.; Langer, J.

Book ID: 122279183
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 59 KB
Volume: 16
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2013.08.664

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Real-World Cost-Effectiveness: Lower Cos

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide

✍ DeKoven, Mitch; Lee, Won Chan; Bouchard, Jonathan; Massoudi, Marjan; Langer, Jak 📂 Article 📅 2014 🏛 Springer Healthcare Communications 🌐 English ⚖ 617 KB

PDB33 The Associated Costs of Treating T

PDB33 The Associated Costs of Treating Type 2 Diabetes Patients to a Clinically Relevant Composite Endpoint With Liraglutide Versus Exenatide

✍ J. Langer; J.R. Bouchard 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PDB6 18 MONTH A1C AND WEIGHT OUTCOMES OF

PDB6 18 MONTH A1C AND WEIGHT OUTCOMES OF EXENATIDE THERAPY IN PATIENTS WITH TYPE-2 DIABETES IN A REAL-WORLD STUDY

✍ D Brixner; C McAdam-Marx; X Ye; D Misurski; M Wintle; R Fabunmi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

PDB22 ‘Real-World' Clinical Outcomes of

PDB22 ‘Real-World' Clinical Outcomes of Exenatide Bid Compared to Insulin Glargine in Patients with Type 2 Diabetes

✍ Pawaskar, M.; Li, Q.; Hoogwerf, B.; Reynolds, M.W.; Faries, D.E.; Bruhn, D.; Ber 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Evaluating the Long-Term Cost-Effectiven

Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents

✍ William J. Valentine; Andrew J. Palmer; Morten Lammert; Jakob Langer; Michael Br 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 505 KB

A1C and weight outcomes at 18 months in

A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

✍ C. McAdam-Marx; X. Ye; D. I. Brixner; R. Fabunmi; M. Wintle; K. S. Boye; D. Misu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB